OTC Markets OTCQB - Delayed Quote USD

NUREXONE BIOLOGIC INC (NRXBF)

0.5680
+0.0362
+(6.81%)
At close: June 8 at 8:00:00 PM EDT
Loading Chart for NRXBF
  • Previous Close 0.5318
  • Open 0.5400
  • Bid 0.5313 x 500000
  • Ask 0.5429 x 300000
  • Day's Range 0.5400 - 0.5600
  • 52 Week Range 0.3556 - 0.6075
  • Volume 35,500
  • Avg. Volume 10,112
  • Market Cap (intraday) 44.308M
  • Beta (5Y Monthly) -0.03
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0800
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 3.50

NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. It develops and commercializes the ExoTherapy platform for production of exosome-loaded nanodrugs. The company is also developing an off-the-shelf, non-invasive, and novel treatment for the reversal or reduction of paralysis caused by spinal cord injury using membrane-bound extracellular vesicles technology, as well as to treat traumatic brain injuries and other neurological conditions. Its technology includes ExoPTEN for the treatment of acute spinal cord injury and glaucoma; and Exosomes as a drug delivery system for regeneration and healing of specific tissues. The company was founded in 2020 and is based in Toronto, Canada.

nurexone.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NRXBF

View More

Performance Overview: NRXBF

Trailing total returns as of 6/10/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

NRXBF
32.09%
S&P/TSX Composite index (^GSPTSE)
7.33%

1-Year Return

NRXBF
60.88%
S&P/TSX Composite index (^GSPTSE)
19.74%

3-Year Return

NRXBF
146.96%
S&P/TSX Composite index (^GSPTSE)
30.34%

5-Year Return

NRXBF
146.96%
S&P/TSX Composite index (^GSPTSE)
68.31%

Compare To: NRXBF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NRXBF

View More

Valuation Measures

Annual
As of 6/9/2025
  • Market Cap

    43.87M

  • Enterprise Value

    43.31M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    33.67

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -115.19%

  • Return on Equity (ttm)

    -234.44%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -5.8M

  • Diluted EPS (ttm)

    -0.0800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    588k

  • Total Debt/Equity (mrq)

    2.36%

  • Levered Free Cash Flow (ttm)

    -2.93M

Research Analysis: NRXBF

View More

Company Insights: NRXBF

Research Reports: NRXBF

View More

People Also Watch